Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's

Recursion Pharmaceuticals (RXRX) closed at $3.01 in the latest trading session, marking a +1.69% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.02%. Elsewhere, the Dow saw an upswing of 0.

Recursion Pharmaceuticals' partnerships, notably with Genentech/Roche and Sanofi, have delivered $500M+ in milestone payments. Read why RXRX stock is a Hold.

Recursion Pharmaceuticals (NASDAQ:RXRX) outlined progress across its clinical pipeline, drug-discovery partnerships and AI-enabled research platform, while lowering its 2026 cash operating expense guidance to $375 million and reaffirming expectations for an operating runway through early 2028.

Recursion Pharmaceuticals shares have been a disaster for investors who've been holding them. After falling by more than half in less than a year, though, the stock could be a bargain now. Here's a look at what went wrong and some upcoming catalysts that ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $2.97, marking a -2.62% move from the previous day. This move lagged the S&P 500's daily loss of 1.52%. On the other hand, the Dow registered a loss of 2.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

Recursion's pitch to its customers, which are major biopharma companies, is that collaborating with it will reduce research and development (R&D) costs and timelines. To accomplish that, it employs a handful of AI-enabled methods to identify the biological ...